• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Risk-based lung cancer screening may prevent more deaths than current guidelines

byEvelyn NguyenandDeepti Shroff Karhade
January 12, 2018
in Chronic Disease, Imaging and Intervention, Oncology, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency.

2. However, the increases in efficiency were attenuated when measured by life-years, quality-adjusted life-years (QALYs), and cost-effectiveness.

Evidence Rating Level: 2 (Good)         

Study Rundown: Current guidelines for lung cancer screening using low-dose computed tomography (LDCT) do not take into consideration long-term survival differences or cost differences between higher- and lower-risk patients.  This cost-effectiveness analysis calculated the value of individualized risk-based criteria for lung cancer screening in comparison to the National Lung Screening Trial (NLST) eligibility criteria.  Using NLST data, researchers stratified 53 086 participants according to their baseline risk for lung cancer mortality.  Using a multistate prediction model, the authors found that targeting risk may improve the efficiency of screening when measured by early lung cancer death per individual screened.  However, the increases in efficiency were attenuated when measured by life-years, QALYs, and cost-effectiveness.  Considering that high-risk patients cost more to screen and have a reduced life expectancy after any lung cancer survival, the authors suggested that using a risk model is not likely to result in considerable improvement in the cost-effectiveness of lung cancer screening using LDCT (as measured by QALYs gained compared to cost).

A strength of this study is that it takes into consideration differences in long-term survival of lung cancer and quantifies the cost differences between higher- and lower-risk patients.  A limitation of this study is that the study design does not take into account all associated differences between the risk of mortality from lung cancer and quality of life.

Click to read the study in Annals of Internal Medicine

RELATED REPORTS

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Relevant Reading: Targeting of low-dose CT screening according to the risk of lung-cancer death

In-Depth [cost-effective analysis]: Using data from the NLST regarding 53 086 participants, researchers stratified the participants into deciles based on their 7-year risk of lung cancer mortality. Researchers used a multistate prediction model to measure several outcomes for LDCT compared to chest radiography for each decile.  The researchers found that participants who had a higher risk of death from lung cancer were older, had more comorbidities, and had increased costs related to screening.  For the first 7 years, 1.2 (lowest risk decile) to 9.5 (highest risk decile) deaths due to lung cancer were prevented per 10 000 person-years.  Across risk groups, the gradient of benefits was lessened when measured in life-years and QALYs, and the incremental cost-effectiveness ratios (ICERs) were comparable.  The ICER was $75 000 per QALY and $53 000 per QALY for the lowest and highest risk deciles, respectively.  Participants willing to spend $100 000 per QALY would obtain LDCT screening for all deciles.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: cancer screeninglung cancerscreening guidelines
Previous Post

Live-birth rates similar among ovulating women undergoing fresh- or frozen-embryo transfer

Next Post

Postnatal cytolomegalovirus infection not linked to impaired motor development

RelatedReports

Lessons from real-world implementation of lung cancer screening
Oncology

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

July 7, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 4, 2025
Patient Basics: Lung Cancer Overview
Chronic Disease

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 2, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
Next Post
Postnatal cytolomegalovirus infection not linked to impaired motor development

Postnatal cytolomegalovirus infection not linked to impaired motor development

Low circulating cholesterol in neonates linked with pyloric stenosis

Broader statin use more likely to prevent cardiovascular events

Infant room-sharing associated with less nighttime sleep and unsafe sleep practices

Urinalysis highly sensitive and specific for UTI in febrile infants

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.